Introduction
Cancer pathogenesis is a long-term process that involves multiple genetic and epigenetic alterations. Extensive research has shown that many molecular abnormalities are involved in cancer development, including chromosomal amplification of oncogenes, gene methylation, gene silencing and transcriptional and translational alterations.
d-Catenin (gene designation as CTNND2) is an adhesive junction-associated protein of the b-catenin superfamily (Paffenholz and Franke, 1997; Zhou et al., 1997; Lu et al., 1999; Paffenholz et al., 1999) . It was mapped to human chromosome 5p15, a region critical for the development of severe mental retardation phenotype in the Cri-Du-Chat syndrome . Although 5p is variably deleted or duplicated in the CriDu-Chat syndrome and other developmental disorders (Marinescu et al., 1999; Medina et al., 2000; Cervera et al., 2005) , it shows gene amplification in some cancers (Zheng et al., 2004; Fatima et al., 2006; Huang et al., 2006) . d-Catenin was initially identified as a neuralspecific protein in the brain (Paffenholz and Franke, 1997; Zhou et al., 1997; Lu et al., 1999; Ho et al., 2000) , interacting with Alzheimer's disease protein presenilin (Zhou et al., 1997; Tanahashi and Tabira, 1999) . Further studies show that d-catenin promotes the disruption of Ecadherin-based adherens junction to favor cell spreading upon stimulation by hepatocyte growth factor (Lu et al., 1999) . Examination of human expressed sequence tag data bank revealed d-catenin mRNA sequences in kidney, ovarian, brain, breast and esophageal tumors. Other studies showed that d-catenin mRNA was overexpressed in prostate cancer compared with benign prostate hyperplasia (Burger et al., 2002) . Recently, we showed that d-catenin protein expression is upregulated in over 80% of prostatic adenocarcinomas, and its expression is correlated with increasing Gleason's scores (Lu et al., 2005) . An increased expression of d-catenin is accompanied by the downregulation of tumor suppressor E-cadherin and p120 ctn in primary prostatic adenocarcinomas. In addition, the forced overexpression of d-catenin in cultured prostate cancer cells disrupted the distribution of E-cadherin and p120 ctn , major cell-cell junction proteins whose inactivation is often linked to the aggressive phenotype of prostate cancer (Umbas et al., 1994; Lu et al., 2005) .
The frequently increased expression of the neuronal protein d-catenin in peripheral tissues of cancer raised important questions such as what mechanisms are in place in cancer to result in a high level of d-catenin expression. Increased d-catenin gene copy number was observed in cervical cancer (Huang et al., 2006) and bladder cancer (Zheng et al., 2004) . In addition, the transcription factor Pax6 was found to play an important role for the regulation of d-catenin expression in developing eye and central nervous system (Duparc et al., 2006) . Recently, we showed that the ectopic overexpressions of E2F1 and Pax6 positively upregulate d-catenin expression in prostate cancer cells (Kim et al., 2008) . To gain further insights into the mechanisms by which d-catenin overexpression is controlled in cancer, we examined the regulation of d-catenin expression in prostate cancer by methylation status and potential gene amplification. We also screened possible nucleotide sequence changes in the promoter and 5 0 -untranslated region (5 0 -UTR) of d-catenin gene by single-strand conformation polymorphism (SSCP) analyses. We discovered an increased incidence of single nucleotide polymorphisms (SNPs) in d-catenin in human prostate cancer specimens. Importantly, a true somatic point mutation in the 5 0 -UTR region of d-catenin was identified in a 70-year-old patient with a high Gleason's score, poorly differentiated prostatic adenocarcinoma. This point mutation was located close to the end of 5 0 -UTR, at position À9 bp with respect to the translation initiation ATG codon. Remarkably, the nucleotide fragment with this point mutation promotes the expression of a chimeric gene-based luciferase reporter. Prostatic tissues bearing this mutation displayed an increased d-catenin expression over normal tissues. Our results support the notion that somatic mutations in 5 0 -UTR of d-catenin can contribute to the alteration of d-catenin expression and provide new insight into d-catenin gene regulation in cancer pathogenesis.
Results

d-Catenin mRNA expression in prostate cancer cells
We examined d-catenin mRNA levels in several widely used prostate cancer epithelial cell lines. CWR22Rv-1 cells were derived from a primary prostate tumor xenograft (Pretlow et al., 1993; Sramkoski et al., 1999) . PC-3 cells were derived from prostate cancer bone metastasis (Kaighn et al., 1979) . LNCaP cells were isolated from the lymph node with confirmed diagnosis of metastatic prostate carcinoma (Horoszewicz et al., 1983) . DU145 cells were isolated from brain metastasis of prostate cancer (Stone et al., 1978) . PZ-HPV-7, a control cell line, was derived from epithelial cells of the peripheral zone of normal human prostate (Weijerman et al., 1994) . Reverse transcription-PCR (RT-PCR) analysis detected d-catenin mRNA in all of the five cell lines examined ( Figure 1a) ; however, although d-catenin mRNA level in PZ-HPV-7, LNCaP and DU145 cells was low, its expression in CWR22Rv-1 and PC-3 cells was considerably high (Figure 1b) . Consistent with our earlier report (Lu et al., 2005) , we also detected d-catenin mRNA overexpression in 8/8 cases of prostatic adenocarcinomas when compared with that of benign prostate tissue specimens (data not shown).
Methylation status of CpG islands around d-catenin transcription initiation site in prostate cancer cells Gene expression can be activated or inactivated by reversible epigenetic events such as DNA methylation alterations in the promoter region (Nakayama et al., 2001; Zhang et al., 2004) . To determine whether changes in DNA methylation could account for different expression levels of d-catenin in normal and cancerous prostatic epithelial cell lines, we analysed the CpG islands in the d-catenin promoter region. According to http://www.urogene.org/, regions of CpG islands were identified from À828 to À57 nucleotides (nt) in relation to the ATG start codon (Figure 1c) . The software predicts the most prominent and PCR amplifiable CpG islands (À281 to À95 nt) around the transcription initiation site (À145 nt). The methylation status of these CpGs islands in d-catenin was examined by nest PCR with the methylation-specific primer sets (Supplementary material S1 Table 1 To investigate further whether the methylation of d-catenin CpG islands is functionally important for the regulation of d-catenin expression, we compared the expression of d-catenin gene in DU145 and CWR22Rv-1 cells by semi-quantitative RT-PCR. The expression of d-catenin with heterozygous methylation status in DU145 cells was the lowest, whereas the expression of d-catenin with no methylation was highest in CWR22Rv-1 cells (Figure 1b) . To test whether demethylation affects the expression of d-catenin, we treated DU145 and CWR22Rv-1 cells with the methyltansferase inhibitor 5-aza-2 0 deoxycytidine (5 0 Aza-DC). Our results showed that 5 mM 5 0 Aza-DC treatment had no effect on d-catenin mRNA levels in either DU145 or CWR22Rv-1 cells (Figure 1e ).
d-Catenin gene copy number in prostate cancer cells Gene amplification and deletion play an important role in the pathogenesis of solid tumors, including prostate cancer (Kindich et al., 2005; Murthy et al., 2005; Ren et al., 2006) . To determine whether gene amplification at chromosome 5p15 could be an underlying mechanism for d-catenin upregulation in prostate cancer, we applied Table 2 . We then applied the absolute quantification method to determine the input copy number by relating the PCR signal to a standard curve (Livak and Schmittgen, 2001 ; see also Supplementary materials S4).
On the basis of this experimental design, we determined the gene copy number of d-catenin in all aforementioned cell lines, normal bloods, normal prostate tissues and primary prostatic adenocarcinomas. We did not observe significant increases in d-catenin gene copy number in normal or prostate cancer specimens ( Figure 2a ). On the other hand, c-myc gene, which was used as a positive control, showed an amplification of three-fold in one prostatic adenocarcinoma in comparison with that of normal prostate tissues ( Figure 2b , a three-fold increase is indicated by an asterisk).
Mutational analysis of d-catenin coding and non-coding sequences
The presence of activating or inactivating mutations in the coding region of proteins can provide important functional implications. We prepared primer sets to cover the entire open reading frame of d-catenin (Supplementary materials S3 Table 3 ). These primer sets divided the full-length d-catenin into eight sequence segments. d-Catenin cDNA was obtained by RT-PCR and the resulting PCR fragments were directly sequenced. From all the prostate cancer specimens described above and the five cases of esophageal cancer tissue samples, we were not able to detect any mutations or truncations. This result suggested that the primary sequence alterations in d-catenin-coding regions may not be common in prostate cancer.
We further examined whether any nucleotide sequence alterations are present in the regulatory elements of d-catenin gene non-coding region. A 204 bp DNA fragment of a promoter and a 5 0 -UTR of d-catenin genomic DNA upstream of an initial translation site was amplified and analysed using the SSCP method (Figures 3a and b) . Polymorphic nucleotide changes with the mobility shifts of DNA fragments were identified in 6 out of 18 prostate cancer tissue specimens (Figure 3a , case nos. 1, 2, 4, 9, 10 and 12) with Gleason's scores ranging from 6 to 9 (Supplementary materials S5 Table 4 ). No SNP was detected in seven normal blood or benign prostatic tissues (data not shown). We then chose to focus on one prostatic adenocarcinoma (case no. 4) to further verify the presence of polymorphism. A 133 bp fragment of promoter and 5 0 -UTR regions of d-catenin genomic DNA upstream of an initial translation site was amplified using a different primer set. Using different primer sets to amplify d-catenin DNA of different sizes ruled out the possibility of PCR errors. The mobility shift was confirmed by SSCP experiment (Figure 3b, arrow) . In this analysis, we included normal blood and normal prostatic tissue, as well as the five prostate epithelial cell lines. Only the prostate cancer case no. 4 with confirmed tumor cell clusters (case no. 4C) isolated by laser microdissection technology consistently showed mobility shift in SSCP analysis (Figure 3b) . Convincingly, this mobility shift in SSCP analysis was not detected in the adjacent benign tissue of case no. 4 (case no. 4N) isolated by laser microdissection. Direct DNA sequencing confirmed the presence of one SNP (À9 G>A) (Figures 3c and d , case no. 4) at the position of À9 from the ATG start codon in a 70-year-old patient with a high Gleason's score 9, poorly differentiated primary prostatic adenocarcinoma. Therefore, this SNP represents a true point mutation associated with prostate cancer. As an additional comparison, we verified that À58 C>T in one prostatic adenocarcinoma case is an SNP, as d-catenin gene sequences with the same change were present in both malignant and the matched adjacent benign prostatic glands isolated by laser microdissection (date not shown).
Increased expression of luciferase reporter gene driven by d-catenin promoter with mutation À9 G>A in 5 0 -UTR The analysis of d-catenin promoter and 5 0 -UTR sequence using Mat Inspector V2.2 predicted the minimal core promoter at À56 nt to À34 nt and a CCAAT/enhance site at À92 nt to À78 nt. The point mutation (À9 G>A) that we discovered was just downstream to these regions. Therefore, we took advantage of this structural feature and directly amplified the sequence of 5 0 -UTR and exon 1 from genomic DNA of d-catenin and subcloned it into the pGL3-basic luciferase reporter system (Figure 4a ).
To examine whether the À9 G>A point mutation specifically affects the expression of d-catenin, we compared the ability of different sequence changes (wild type and mutated forms) in d-catenin 5 0 -UTR to drive luciferase reporter expression and activity. Luciferase expression vectors containing wild-type, M-9 (À9 G>A), M-32 (À32 G>A) and M-97 (À97 T>A) DNA sequences were constructed (Figure 4a) . These vectors were then transfected into prostate cancer CWR22Rv-1 and non-cancer PZ-HPV-7 cells, respectively. The luciferase activities, as shown in Figure 4b , represent the average values of three independent experiments. Under this experimental condition, M-9 transfection produced a 6-to 14-fold higher luciferase activity than that of pGL3-basic vector control or a 3-to 7-fold higher luciferase activity than that of wild-type construct, depending on the different cell lines transfected (Figure 4b , left panel, CWR22Rv-1 cells; right panel, PZ-HPV-7 cells). In contrast, M-32 and M-97-transfected cells did not show significant increases in luciferase activity when compared with that of wild-type sequence.
To distinguish whether the observed differences in luciferase activity between cells transfected with wild-type and mutant d-catenin 5 0 -UTRs were caused by an alteration of transcription or translation efficiency of the mutant forms, we analysed the levels of chimeric mRNAs in the transfected cells. Extracted mRNAs were treated with DNase to eliminate the possible contamination from plasmid DNA (date not shown). Real-time PCRs were performed using the primers covering the whole 5 0 -UTR and the part of luciferase mRNA to ensure the transcription of inserted 5 0 -UTR. No significant differences at the mRNA level were observed, indicating that the transcription efficiency and RNA stability were similar for all chimeric mRNAs (Figure 4c ).
d-Catenin expression in prostatic adenocarcinomas with mutation À9 G>A in 5 0 -UTR Our earlier studies showed that the expression of d-catenin mRNA and protein is increased in prostatic adenocarcinoma (Lu et al., 2005) . Consistent with our earlier report, we found that d-catenin expression in the prostatic adenocarcinoma harboring mutation À9 G>A in d-catenin 5 0 -UTR was also increased compared with that of benign prostatic tissues ( Figure 5A ). In addition, the immunohistochemical analysis showed that although anti-d-catenin immunoreactivities were weak in normal prostatic glandular epithelial cells ( Figure 5B ,a and 5B,c), their activities were clearly increased in the prostatic adenocarcinoma harboring this mutation ( Figure 5B,b and 5B,d).
Discussion
Understanding how gene expression is regulated plays important roles in the elucidation of gene functions in human cancer. Although d-catenin gene amplification was reported in cervical (Huang et al., 2006) and bladder cancer (Zheng et al., 2004) , d-catenin overexpression at the transcriptional level has been documented in prostate cancer (Burger et al., 2002; Lu et al., 2005) . Our current studies show that multiple mechanisms probably account for the upregulation of d-catenin Using RT-PCR, we have shown that d-catenin expression was increased in prostate cancer cell lines such as CWR22Rv-1 and PC-3, when compared with that of non-cancer prostate epithelial cell PZ-HPV-7. However, two other prostate cancer cell lines LNCaP and DU145 did not show an increased d-catenin expression. This raised questions as to whether d-catenin overexpression is absolutely required in prostate cancer progression. As not all prostatic adenocarcinomas showed d-catenin overexpression, it seems more likely that d-catenin is one of many oncoproteins that contribute to tumorigenesis. It is also possible that increased d-catenin expression may occur at certain stages of prostate cancer progression.
Unlike all the other prostate cell lines we have tested, DU145 cells showed a heterozygous hypermethylation status in d-catenin gene promoter. Treatment of cells with methyltransferase inhibitor 5-deoxyazacytidine did not increase d-catenin expression, suggesting that hypermethylation is not the major mechanism for regulating d-catenin gene expression in DU145 cells. We also did not find any significant increases in gene copy numbers in prostate cancer cell lines or from the prostate cancer tissue specimens that we have tested. Therefore, although d-catenin gene amplification occurs in cervical (Huang et al., 2006) and bladder cancer (Zheng et al., 2004) , it cannot be a major mechanism for d-catenin overexpression in prostate cancer. In contrast, transcriptional upregulation appears to play important roles in d-catenin overexpression in at least some prostate cancer cases. Indeed, recently, we found that A DNA construct with a À9 G>A point mutation produced a three-to seven-fold higher luciferase activity, in contrast to À32 or À97 point mutant as controls, as well as compared with the wild type (*Po0.005). (c) Real-time PCR showed that there was no significant differences in transcriptional efficiency among DNA constructs containing wild-type, À9 G>A, À32 G>A or À97 G>A mutation. (Kim et al., 2008) . Interestingly, although Pax6 expression is correlated with pancreatic adenocarcinomas, and differentiation caused its downregulation (Lang et al., 2008) , Pax6 expression suppresses glioblastoma cell invasiveness (Mayes et al., 2006) . In the future, it will be important to determine how Pax6 expression may be involved in the regulation of d-catenin overexpression in prostate cancer.
Besides the transcriptional regulation, translation efficiency also contributes to the expression of proteins, and this is especially true if the alteration of gene sequences occur at the promoter and 5 0 -UTR proximal to the translation initiation site. For example, high glucose condition increased the mRNA translation efficiency of CD36 in hyperglycemia (Griffin et al., 2001) . On the other hand, it was found that a somatic mutation in the 5 0 -UTR of BRCA1 gene in sporadic breast cancer caused downmodulation of translation efficiency (Signori et al., 2001) . In our present study, we have discovered an increased incidence of gene mutations in d-catenin promoter and 5 0 -UTR associated with prostate cancer. Remarkably, although we consistently detected the nucleotide changes by SSCP in prostate cancer specimens, we have not observed any such SNPs in normal control specimens, indicating that the changes were quite frequent in prostate cancer. However, although À9 G>A mutation occurred only in cancerous tissues, not all SNPs manifested cancer-specific patterns. For example, À32 G>A sequence change occurred in both cancerous and adjacent benign tissues. Therefore, we speculate that d-catenin 5 0 -UTR may be particularly susceptible to oxidative or other DNA damage attack to introduce mutations. Not all SNPs in d-catenin 5 0 -UTR show cancer-related alteration of its gene expression. But the increased chances in nucleotide changes can increase the possibility of shifting the balance toward cancer-specific expression. Future studies will be needed to explore what tumor microenvironment factors promote the occurrence of mutations in d-catenin gene promoter and 5 0 -UTR.
Materials and methods
Cell lines and tissue specimens
All human prostate cancer or non-cancer cell lines were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA) and were cultured according to the manufacturer's instruction at 37 1C with 5% CO 2 atmosphere. A total of 25 cases of human prostate cancer and benign specimens were analysed in this study. Total RNAs were obtained either from prostate cancer and matched adjacent non-cancer tissue commercially (Ambion, Austin, TX, USA; Clontech, Mountain View, CA, USA) or from fresh prostate cancer tissues in house. Fresh and paraffin-embedded noncancer prostate tissues and primary prostatic adenocarcinoma samples for DNA analyses were obtained after radical prostatectomy from previously untreated patients at East Carolina University Brody School of Medicine. For some experiments, we also used normal blood as an additional noncancer specimen control. All samples were collected according to the East Carolina University Institutional Research Board (IRB) approved protocol and further verified by pathological analysis.
DNA extraction, RNA isolation and RT-PCR Genomic DNA from fresh and paraffin-embedded tissues after deparaffinizing using xylene was isolated using the DNeasy Tissue Kit (Qiagen Science, Valencia, CA, USA). Genomic DNA of matched adjacent benign prostatic glandular epithelial cells captured from paraffin-embedded sections using Laser Capture Microdissection (Zeiss, Germany) was extracted using the PicoPure DNA Extraction Kit (Arcturus Bioscience, Mountain View, CA, USA). Total RNAs were isolated using the RNeasy Mini kit (Qiagen Science). Reversed transcription was performed using SuperScript II (Invitrogen, Carlsbad, CA, USA). Semi-quantitative RT-PCR analysis was used to determine gene expression of d-catenin at mRNA level in cell lines, normal prostate tissues and prostate cancers and of luciferase in transfected cell lines. The PCR primers used to Table 3 ). The expression of GAPDH was used as a control. For comparing the expression of luciferase after transfecting different DNA sequences in each cell line, the pairs of primers for luciferase included the forward sequence 5 0 -GCTCAGACAACAAAAGCGGAAGAT-3 0 and reverse sequence 5 0 -TCCAGATCCACAACCTTCGCTTCA-3 0 . In these experiments the expression of b-galactosidase was used as a control.
Bisulfite modification and nest PCR using methylation-specific primers Bisulfite treatment of the genomic DNA was performed using a bisulfite modification kit (Active motif, CA, USA). In the bisulfite reaction, all unmethylated cytosines were deaminated and converted to uracils, whereas 5-methyl cytosines remained unaltered. The modified DNA was subjected to PCR amplification using outer primers, and nest PCR was performed using the methylation-specific primers, which were designed using the MethPrimer website (http://www.urogene. org/methprimer/). The U primer sets were annealed to unmethylated DNA that had undergone chemical modification, whereas M primer sets were annealed to modified, methylated DNA. W primer sets served as a control by annealing to wild-type DNA that had not undergone modification. All sequences of these primers were listed in Supplementary material (S1, Table 1 ). To determine whether demethylation affects the expression of d-catenin in prostate cancer cell lines, DU145 and CWR22Rv-1 cells were treated with 5 mM methyltansferease inhibitor 5 0 Aza-DC (Sigma Corp, St Louis, MO, USA).
Quantitative real-time PCR and gene amplification Real-time PCR was performed using an SYBR Green PCR Master Mix in an iCycler iQ Multicolor Real-time PCR Detection System (Bio-Rad, Hercules, CA, USA). To measure d-catenin gene copy number in prostate cancer samples, we used an absolute quantification method that determines the input copy number, by relating the PCR signal to a standard curve (Livak and Schmittgen, 2001) . The primers used for the analysis were listed in Supplementary material S2 Table 2 . Primers were designed according to exon 6 of GAPDH gene (12p13) as an internal reference gene, exon 11 of d-catenin gene (5p15) and exon 3 of c-myc gene (8q24) by using a web-based program at http://www.idtdna.com and synthesized from IDT (Coralville, IA, USA). Qiagen purified PCR products were subcloned into a TOPO-TA vector (Invitrogen, Carlsbad, CA, USA). Positive clones were confirmed by digestion with EcoRI and by DNA sequencing. Qiagen purified DNA with the inserts was measured by ultraviolet absorbance, and copy number was calculated for each insert by the following formula: gene copy number ¼ ng Â 10 À9 Â 6.02 Â 10 23 /molecular weight. Serial dilutions ranging from 10 8 to 10 3 copies were prepared for real-time PCR of d-catenin, GAPDH and c-myc genes, respectively, in duplication, and individual standard curves were constructed (Supplementary material S4). These curves were used as standards for the quantitative analysis of copy number of the unknown prostate cancer samples using threshold cycle (C t ) value by the iCycler. The PCRs for dcatenin, GAPDH and c-myc gene were always run simultaneously using the same volume for each sample in duplication. The absolute gene copy number of d-catenin and c-myc was determined by the ratio between d-catenin and GAPDH, and between c-myc and GAPDH mean copy number in each duplicate.
PCR-SSCP analysis
Screening of potential mutations in d-catenin promoter and 5 0 -UTR was performed using two sets of primers for amplification. Forward primer 5 0 -TGCCGCCCGCCAGCATCCC TTGT-3 0 and reverse primer 5 0 -AGCCCCGCAACTCACCC AAAGGCG-3 0 were used for PCR of DNA sequence with a size of 204 bp located at 5 0 -UTR region and exon 1. Forward primer 5 0 -GCTCAGACAACAAAAGCGGAAGAT-3 0 and reverse primer 5 0 -TTCCTCGCAAACATGCACCCT-3 0 were used to obtain a PCR fragment with a size of 133 bp located at 5 0 -UTR region and exon 1. A mixture consisting of PCR product and SSCP stop dye (98% deionized formamide, 0.5 M EDTA, 0.25% bromphenol blue and 0.25% xylene cyanol) was heated for 10 min, and then plunged into ice prior to loading onto the gel.
A 4-20% gradient polyacrylamide TBE gel electrophoresis (Invitrogen, Carlsbad, CA, USA) was used to run samples at 300 V for 5 min followed by running at 100 V for 6 h. The temperature of the buffer chamber was kept between 4 and 10 1C and was monitored during the electrophoresis.
DNA sequence analysis PCR fragments amplified from d-catenin cDNAs were sequenced directly. PCR products of interest obtained from PCR-SSCP were ligated into a TOPO-TA vector. Multiple clones were confirmed by digestion with EcoRI and sequenced. The DNA sequences of amplified PCR fragments obtained from prostate cancer tissues and the matched adjacent normal prostate cells were compared with d-catenin DNA sequence as a reference published in the National Center for Biotechnology Information database using BLAST Program.
Plasmid construction of luciferase reporter system
The 133bp fragments containing 5 0 -UTR and exon 1 of wild type, M-9 (a À9 point mutation G>A that resembles the gene mutation in case no. 4 of prostatic adenocarcinoma), M-32 (a À32 point mutation G>A that was randomly selected) and M-97 (À97 mutation T>A that disrupts the only upstream open reading frame) were PCR-amplified by using forward primer 5 0 -CCCTCGAGGCTCAGACAACAAAAGCGGAA-GAT-3 0 and reverse primer 5 0 -CCAAGCTTTTCCTCGC AAACAAGCACCCT-3 0 . M-58, another fragment of 133 bp of the same region (a À58 point mutation C>T from the start codon ATG, which reflects a natural mutation in a prostatic adenocarcinoma) was also PCR-amplified but verified as polymorphism from a prostate cancer patient. These fragments were subcloned into a TOPO-TA vector, and positive clones were confirmed by digestion with EcoRI and by DNA sequencing. The insert fragments were digested from a TOPO-TA vector by HindIII and NcoI and ligated into pGL3-basic reporter vector (Promega, Madison, WI, USA).
Transient co-transfection assay CWR22Rv-1 and PZ-HVP-7 cells were transfected using Fugene 6 (Roche, Indianapolis, IN, USA) with 1.0 mg of pGL3-basic reporter vector, wild type, M9, M-32, or M-97 along with 0.5 mg of pCMV-b-gal plasmid (Promega). The pGL3-basic reporter vector containing luciferase gene was used as a background control. pCMV-b-gal contains the b-galactosidase gene driven by CMV promoter and was used as a control for transfection efficiency. Luciferase and b-galactosidase activities were measured using the Luciferase and b-Galactosidase Assay Systems (Promega). Luciferase activity was read in a FLUROSKAN ASCENT FL (Thermo Electron Corporation, Vantaa, Finland). Luciferase values were normalized to b-galactosidase for each experiment, and d-Catenin SNPs and prostate cancer T Wang et al adjusted for fold expression over that of the pGL3-basic reporter expression for each cell line tested.
Immunochemistry and immunohistochemistry
Fresh prostate cancer and benign prostate tissues were homogenized in a radioimmuno precipitation assay buffer (150 mM NaCl, 10 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), pH 7.3, 2 mM EDTA, 0.2% SDS, 0.5% sodium deoxycholate, 1% Triton X-100) supplemented with protease inhibitors (Roche Complete Protease Inhibitor cocktail), followed by 30 min incubation on ice. Cell debris was removed by centrifugation. Supernatant was collected and protein concentration was determined using the Pierce BCA assay (Pierce Biotechnology, Rockford, IL, USA). Samples were heated and loaded on SDS-polyacrylamide gel electrophoresis gels, transferred to nitrocellulose membrane and subject to western blot analysis. For tissue immunohistochemistry, 5 mm tissue sections of formalin-fixed, paraffin-embedded blocks were deparaffinized and rehydrated. Endogenous peroxidase was blocked by incubation with hydrogen peroxide. The sections were immunostained in a Dako Autostainer (Carpinteria, CA, USA) using rabbit anti-d-catenin (1:100) (Abcam, Cambridge, MA, USA) followed by the streptavidin-biotin peroxidase method for detection.
Statistical analysis
For semi-quantitative RT-PCR and luciferase reporter experiments, all results were reported as mean ± s.e.m. and statistical analysis was conducted using one-way analysis of variance. For quantitative real-time PCR, all data were reported as mean ± s.e.m. and the statistical analysis was conducted using Duncan's test. The significance levels were set at either Po0.005 or Po0.05.
